Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer in Diverse and Low-Resource Settings
JCO Global Oncology · 2026-05 · 12 (5)
DOI: 10.1200/go-25-00705 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2026-05. Verfasst von Rubem Jose Peres Moreira und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Instituto Nacional de Cancer, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Genomic assays are commonly used to predict breast cancer recurrence but remain inaccessible in low-resource settings, often leading to unnecessary chemotherapy. We previously optimized a LASSO-penalized regression model incorporating quantitative clinicopathologic features to predict genomic risk. Here, we present validation and clinical utility in an international cohort. METHODS We retrospectively analyzed patients with early-stage hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer treated in Chicago and Rio de Janeiro. Model accuracy for predicting high Oncotype DX (ODX) scores was evaluated using area under the receiver operating characteristic curve (AUROC) in Chicago cohorts. Survival outcomes—disease-free interval (DFI), disease-free survival (DFS), and overall survival (OS)—were compared by Kaplan-Meier and Cox regression using a predefined threshold for high-risk disease. Adjusted models examined chemotherapy benefit by predicted risk. Estimated cost was compared between testing strategies and chemotherapy allocation in Brazil and the United States. The study was approved by the Brazilian Research Ethics Committee on October 24, 2024, under CAAE number 67993323.6.0000.5274. Due to the retrospective nature of the study, which involved only data collection from electronic medical records, the requirement for informed consent was waived by the Ethics Committee. Additionally, the study is covered under Institutional Review Board 22-0707 at the University of Chicago. RESULTS We included 1,566 patients from Chicago and 296 from Rio de Janeiro. The estrogen receptor/progesterone receptor/Ki-67 model showed strong performance for ODX prediction (AUROC 0.81 and 0.91).Compared with high-risk patients, low-risk patients had superior 5-year DFI (98.0% v 81.6%, hazard ratio [HR], 11.89, P < .001), DFS (91.3% v 77.5%, HR, 3.41, P < .001), and OS (92.1% v 87.3%, HR, 2.47, P = .02). Chemotherapy provided no significant benefit in the low-risk group. CONCLUSION Our model accurately predicted recurrence and outcomes across US and Brazilian cohorts, supporting treatment de-escalation in low-risk patients and promoting equitable care where genomic testing is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
- Medical Oncology, Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.
- Pritzker School of Medicine, University of Chicago, Chicago, IL.
- Department of Public Health Sciences, University of Chicago, Chicago, IL.
- Department of Medicine, NorthShore University HealthSystem, Evanston, IL.
- Department of Pathology, NorthShore University HealthSystem, Evanston, IL.
ORCID-Profile: Rubem Jose Peres Moreira, Jose Bines, Jincong Q Freeman, Poornima Saha, Megan E Sullivan, Dezheng Huo, Alexander T Pearson, Isabele Avila Small, Olufunmilayo I Olopade, Frederick Matthew Howard
Förderung
- NCI NIH HHS
- NIA NIH HHS
Zitieren
APA
Peres Moreira, R. J., Bines, J., Dhungana, A., Freeman, J. Q., Saha, P., Sullivan, M. E., Yao, K., Flores, E. M., Huo, D., Pearson, A. T., Small, I. A., Olopade, O. I., & Howard, F. M. (2026). Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Global Oncology, 12(5). https://doi.org/10.1200/go-25-00705
Vancouver
Peres Moreira RJ, Bines J, Dhungana A, Freeman JQ, Saha P, Sullivan ME, et al. Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Global Oncology. 2026;12(5). doi:10.1200/go-25-00705
BibTeX
@article{PeresMoreira2026,
author = {Peres Moreira, Rubem Jose and Bines, Jose and Dhungana, Asim and Freeman, Jincong Q and Saha, Poornima and Sullivan, Megan E and Yao, Katharine and Flores, Elbio M and Huo, Dezheng and Pearson, Alexander T and Small, Isabele Avila and Olopade, Olufunmilayo I and Howard, Frederick Matthew},
title = {Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer in Diverse and Low-Resource Settings},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {5},
doi = {10.1200/go-25-00705}
}
EUVIMED